Related Experiment Video
Updated: Jun 9, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Leveraging Large Language Models to Extract Prognostic Pathology Features in Ewing Sarcoma
Jingwei Huang1, Ayesha Batool2,3, Zifan Gu1
1O'Donnell School of Public Health, UT Southwestern Medical Center Dallas.
Background:
Current risk stratification for Ewing sarcoma relies heavily on clinical factors such as metastatic status, failing to capture histologic heterogeneity as a potential prognostic indicator. Although pathology reports contain rich biological data, this information remains locked in unstructured narrative text, limiting large-scale retrospective analyses. We aimed to validate the utility of Large Language Models (LLMs) for scalable data abstraction and to identify prognostic histologic features from a large multi-institutional cohort.
Methods:
We conducted a retrospective cohort study using data from six Children's Oncology Group (COG) clinical trials. We utilized an LLM-based pipeline (OpenAI o3) to extract structured variables-including immunohistochemical (IHC) markers and CD99 staining patterns-from digitized, Optical Character Recognition (OCR)-processed pathology reports. Extraction accuracy was validated against a human-annotated ground truth (n=200) and cross-validated against senior experts (n=48). We assessed the association between extracted features and Overall Survival (OS) using Kaplan-Meier analysis and multivariable Cox proportional hazards regression, adjusting for metastatic status.
Findings:
We analyzed 931 diagnostic pathology reports from 185 institutions spanning over 21-years. The LLM achieved a weighted average accuracy of 94% across 17 IHC markers; in a cross-validation subset, the LLM outperformed human annotators (weighted average accuracy over 15 IHC markers: LLM o3: 98.1%, a pediatric resident 91.4%, and a pediatric oncologist 95.9%). Survival analysis identified Neuron-Specific Enolase (NSE) and S100 as significant prognostic biomarkers. After adjusting for metastatic status, NSE positivity was associated with significantly inferior survival (HR 2.15, 95% CI 1.15-4.02, p=0.016); this risk was most pronounced in patients with non-metastatic disease (HR 5.64, p=0.0055). Conversely, S100 positivity was associated with improved survival (HR 0.58, 95% CI 0.34-1.00, p=0.046).
Interpretation:
LLM-assisted extraction of pathology variables is highly accurate and scalable, capable of unlocking "dark data" from historical clinical trials. We identified NSE as a potent risk factor and S100 as a protective marker in Ewing sarcoma, particularly in localized disease. These findings suggest that AI-derived histologic data can refine risk stratification and, if validated, warrant inclusion in future prospective trials.

